Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Micromet Inc (MITI) -- Ignore unavailable to you. Want to Upgrade?

To: Saulamanca who wrote (75)	4/24/2009 4:29:58 PM
From: Arthur Radley	Respond to of 196

Pivotal Trial Expected to Initiate in 2010 for Blinatumomab NEW YORK, April 24 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today held an R&D Day for investors and financial analysts at The Yale Club of New York City. The presentations highlighted significant areas of development across Micromet's BiTE antibody platform and included updates on: -- BiTE antibody Blinatumomab -- a rapid path to market has been identified for Acute Lymphoblastic Leukemia (ALL) with a registration trial planned to begin in 2010. Dose escalation continues in the study of blinatumomab for non-Hodgkin's lymphoma, with final results expected to be reported at the American Society of Hematology meeting in December. -- BiTE antibody MT110 -- data presented at this week's annual meeting of the American Association for Cancer Research (AACR) demonstrated MT110 can direct T cells to eliminate EpCAM-expressing human colorectal cancer stem cells in cell culture and in animal models. EpCAM is a target antigen that is highly and frequently expressed on many types of solid tumors. MT110 currently is in a phase 1 dose-escalating clinical trial in patients with lung or gastrointestinal cancer. -- EGFR BiTE Antibody -- pre-clinical data presented at AACR demonstrated that BiTE antibodies developed from the EGFR-specific monoclonal antibodies Erbitux(R) (cetuximab) and Vectibix(R) (panitumumab) were highly active against KRAS-and BRAF-mutated human colorectal cancer cell lines. Recent clinical studies have shown that patients with tumor cells harboring mutations in KRAS and BRAF oncogenes do not respond to treatment with Erbitux or Vectibix. These patients make up more than 40% of colorectal cancer patients. "Micromet has developed one of the industry's most extensive and exciting antibody pipelines. Our BiTE antibody platform continues to gain validation in the clinic leading to the planned initiation of a pivotal trial for ALL next year," said Micromet President and CEO Christian Itin. "Micromet continues to advance pre-clinical and clinical programs independently and with its partners Bayer Schering, Nycomed, Merck Serono and MedImmune." An archive of the event's presentations is available at www.micromet-inc.com. About Micromet